October 29, 2014
By Riley McDermid, BioSpace.com Breaking News Staff
The world’s third largest biotech, Amgen Inc , said Tuesday it will use the money it saves from cutting 20 percent of its workforce, or 4,000 jobs, to double down on research, new products and the rollout of its existing blockbuster drug pipeline.
Amgen will improve margin costs by 15 percent by cutting an additional 1,100 jobs to the 2,900 it announced it would axe last summer, the company told analysts Tuesday. The new corporate model will see a total enterprise annual savings of up to $1.5 billion by 2018, said Amgen in a statement.
As it restructures, the company said it will now focus on the discovery and development of innovative medicines to address serious illnesses, the development of branded biosimilars and global expansion. Amgen saw record high third quarter earnings and revenue and had a blockbuster period for its flagship drugs, despite having to take $375 million haircut related to massive restructuring moves announced last summer.
“[They] announced about $800 million in operating expense savings by 2018 [which] includes $1.5 billion in savings due to restructuring and future increased Enbrel profitability, and partially offset by Onyx acquisition costs and growing business costs,” said Mark Schoenebaum, a biotech analyst with ISI Group, in a note to investors. “Due to a new model which includes more variable costs, Amgen has high confidence they can achieve operating margin target going forward.”
Amgen earned $2.30 per share, exceeding analysts’ average expectations by 19 cents, and said it now expects 2014 adjusted earnings of $8.45 to $8.55 per share, an even steeper climb than the enhanced estimate it provided in July of $8.20 to $8.40 per share.
The company told analysts it will be creating new manufacturing technologies at a new unnamed facility in a process that they expect could reduce the cost per gram of proteins by 60 percent or more over time.
As part of that push, it will add three new biosimilars to its six existing drugs, adilimumab, trastuzumab, bevacizumab, infliximab, rituximab and cetuximab. Amgen said two of its current biosimilars, infliximab and rituximab, have advanced to the “clinical ready” phase. Amgen‘s first biosimilar is expected to launch in 2017, followed by four others through 2019.
“On average, Amgen biosimilars cost about $200 million to bring to market,” said Schoenebaum. “[But] Amgen’s target biosimilar market is much larger than the one in which Amgen has existing assets [which means] larger opportunity.”
Anthony Hooper, executive vice president of global commercial operations at Amgen, said there will be a potential doubling of Amgen’s product portfolio over the next three years and said the company will pinpoint specialty market experience; the rollout of its current portfolio of growth phase products; and a continuing move into new geographic growth markets.
Approximately $2 billion in sales in new and emerging markets in Asia, Turkey and the Middle East, Latin America, Russia and Eastern Europe are anticipated by 2018."This is an exciting new era for Amgen. We are on the cusp of an important new product cycle with our rich pipeline of innovative and biosimilar medicines that address important societal needs,” said Robert Bradway, chief executive of Amgen, in a statement.
As for specific drug markets it could targeting with biosimilars, Amgen estimated that inflammation therapy Enbrel (etanercept) is expected to reach $5 billion in sales ahead of Amgen‘s biosimilar adililumab launch, while nephrology competitor Sensipar has the potential to reach approximately $1.5 billion in sales before patent expiry in 2018. Bone drug Prolia’s (denosumab) U.S. share has quadrupled over the past two years, annualizing at $1 billion in sales in 2014. Oncology and cardiac drugs will also be a primary part of its new drug strategy, said executives.
“Our significantly expanded global presence and new biomanufacturing technologies give us confidence that Amgen is uniquely positioned to capitalize on the latest wave of opportunity for innovative biologic therapies,” said Bradway.
Much of the strength of Amgen’s third quarter earning rested on the success of its blockbuster drug pipeline. It saw sales of osteoporosis treatment Prolia skyrocket 43 percent to $255 million, while multiple myeloma cancer therapy Kyprolis brought in $94 million, a significant jump from the Street’s consensus estimate of $87 million. Its treatment for raising the white blood cell count, Neulasta, gained 5 percent to $1.19 billion.
